Rivaroxaban and interventional therapy for acute pulmonary embolism
10.3760/cma.j.issn.1007-631X.2018.10.014
- VernacularTitle:利伐沙班在急性肺动脉栓塞介入治疗中的应用
- Author:
Yongkang DANG
1
;
Xuechao JIANG
;
Liu YANG
;
Jianquan GUO
;
Yongtao BAO
;
Xiangyang TONG
Author Information
1. 赤峰市医院血管外科
- Keywords:
Pulmonary embolism;
Radiography,interventional;
Anticoagulation;
Rivaroxaban
- From:
Chinese Journal of General Surgery
2018;33(10):853-856
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the safety and efficacy of rivaroxaban after interventional treatment of pulmonary embolism.Methods Patients with acute pulmonary embolism undergoing pulmonary indwelling catheter thrombolysis at Chifeng Municipal Hospital from Jun 2016 to Jun 2017 were divided into a group of 23 patients,who afterwards receiving rivaroxaban as a long-term anticoagulant,and that of 45 patients treated with traditional anticoagulant therapy (low molecular weight heparin bridged warfarin).Results The short and mid-term follow-up for the cure rate in the rivaroxaban group was higher than that in the traditional anticoagulation group (60.9％ vs.35.6％,P ＜0.05,and 73.9％ vs.44.4％,P ＜0.05).The incidence of adverse reactions such as bleeding (4.3％) was significantly lower than that of the heparin warfarin group (28.9％),there was no recurrence of venous thromboembolism (VTE) in the rivaroxaban group,and 3 cases in the traditional anticoagulant group;there was no death in either group.Conclusions In the interventional treatment of acute pulmonary embolism,single-agent oral rivaroxaban is equivalent to low-molecular-weight heparin-bridged warfarin;rivaroxaban can effectively reduce pulmonary embolism and the occurrence of bleeding complications after endovascular intervention.
